A 51-Year-Old Woman with Diffuse Large B-Cell Lymphoma

Gilles Salles, MD, PhD, presents the case of a 51-year-old woman with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).

An oncologist describes the typical major challenges of managing patients with R/R DLBCL and the incidence of relapsed or refractory disease.

Dr Salles provides an overview of the available third-line treatment options for patients with R/R DLBCL who are ineligible for or do not wish to receive autologous stem cell transplant or CAR T-cell therapy.

A review of population, dosing, and efficacy data from the GO29365 clinical trial investigating the combination of polatuzumab, bendamustine, and rituximab (pola-BR) for R/R DLBCL.

Gilles Salles, MD, PhD, explains data on the adverse events seen with the pola-BR regimen in R/R DLBCL during the GO29365 clinical trial.

Dr Gilles Salles shares his opinion on the presented case’s treatment decision and the regimen he would have selected for the patient.

Closing out the program, Dr Gilles Salles highlights currently unmet needs in DLBCL and investigational treatments he finds exciting.